In this issue:
Estimating complete skin clearance of plaque psoriasis with biologics
Apremilast for psoriasis
Tofacitinib effects on skin in PsA patients
TYK2/JAK1 inhibitor PF-06700841 for plaque psoriasis
Infantile infection and paediatric psoriasis
IL-17 switching in patients with psoriasis
Clinical outcomes of COVID-19 in TNFi or methotrexate recipients
Reduced mortality with systemic psoriasis treatment
Biologic drug survival rates in the era of anti-IL-17 antibodies
Please login below to download this issue (PDF)